Sionna Therapeutics shares plunge 92% as SION-719 misses Phase 2a endpoint

SION Sionna Therapeutics Inc

$4.75 -2.06%

View chart & analysis →

TENX -1.53% VRTX -0.24%

1. 1Sionna Therapeutics (SION) shares plunged 92% on Monday after the company reported disappointing proof-of-concept Phase 2a results for SION-719 in cystic fibrosis
2. 2In the PreciSION CF trial, the placebo-adjusted change in sweat chloride with Trikafta combination therapy was -1.0 mmol/L (p=0.7), missing the key efficacy endpoint
3. 3The miss represents a major setback for the SION-719 program, prompting a shift in development strategy, with the company planning to preserve capital using its approximately $268.3 million in cash

Source InvestorsHub +3 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →